SecProbe.io

CORRESP
 1
 filename1.htm

 March
20, 2025

 Securities
and Exchange Commission

 Division
of Corporate Finance

 100
F Street, NE

 Washington,
D.C. 20549

 Attn:
Mr. Robert Augustin and Ms. Jane Park

 Re:
Caring Brands, Inc.

 Amendment
No. 3 to Draft Registration Statement on Form S-1

 Submitted
February 11, 2025

 CIK
0002020737

 Dear
Mr. Augustin and Ms. Park:

 Please
find below our responses to the questions raised by the staff (the " Staff ") of the Securities and Exchange Commission
(the " Commission ") in its letter of comments dated February 26, 2025 (the " Comment Letter") relating
to the Amendment No. 3 to the draft registration statement on Form S-1, which was submitted to the Commission by Caring Brands, Inc.
(the " Company " or " we ") on February 11, 2025.

 The
Company's responses are numbered to correspond to the Staff's comments. For your convenience, each of the Staff's comments
contained in the Comment Letter has been restated in bold .

 We
have also updated the Registration Statement on Form S-1 (" Registration Statement ") which is submitted to the Commission
simultaneously together with this letter.

 Amendment
No. 3 to Draft Registration Statement on Form S-1 submitted February 11, 2025

 Prospectus
Summary, page 1

 1.
 We
 note your revised disclosure in response to prior comment 1 relating to the prevalence rates of psoriasis and vitiligo treatments
 in India. Please revise here and elsewhere in the registration statement to disclose the estimated market sizes for the phototherapy,
 psoriasis and vitiligo treatments in India accordingly.

 Response : As
discussed with the Staff, the Company was not able to obtain statistics on the overall market size for the phototherapy market and
the two conditions in India. For the information included in the Registration Statement, we have hyperlinked the articles and
formalized the citations to allow a user to identify and review the sources. As per our discussions with the Staff, we have
clarified which market we are discussing and confirmed that there can be no assurance that the Company's products will be able
to address the total market. We further confirm that no reports referred to in the Registration Statement were commissioned by
the Company for inclusion. As per our call, please advise if you would like us to supplementally provide you with any of the
articles.

 Clinical
Trials of Our Products, page 42

 2.
 We
 note your response to our prior comment 4 and reissue it in part. Please revise your characterization of your trials to discuss the
 data, such as explaining the pre and post-treatment averages in Trial 1, rather than drawing conclusions from the results.

 Response :
We acknowledge the comment and respectfully advise the Staff that we have revised the relevant disclosures to address the comment.

 Research
and Development and License Agreements, page 44

 3.
 We
 note your revised disclosure in response to prior comment 5, which we reissue in part. Please revise to clarify the current status
 of NOVODX's patent applications, including whether NOVODX has submitted its patent applications.

 Response:
 We acknowledge the comment and respectfully advise the Staff that we have revised relevant disclosures to include the following language:

 " As
of the date of this prospectus, NOVODX has not yet submitted any patent applications. NOVODX is in the process of preparing these applications
and evaluating entry into specific jurisdictions. "

 Should
you have any questions regarding the foregoing, please do not hesitate to contact me or our counsel with any questions or comments regarding
this correspondence on the revised and updated Registration Statement.

 Very
 truly yours,

 By:
 /s/
 Glynn Wilson

 Name:
 Glynn
 Wilson

 Chief
 Executive Officer